United States

BRANY to collaborate with U of Miami

Wednesday, May 23, 2012 01:50 PM

BRANY (Biomedical Research Alliance of New York) has agreed to provide education content for the Collaborative Institutional Training Initiative (CITI) at the University of Miami for use on their online clinical research training program.

More... »


FDA-led research discovers autoimmune mechanism for drug-induced AEs

Tuesday, May 22, 2012 02:15 PM

A team of researchers led by the FDA has discovered a new mechanism for identifying and understanding drug-related autoimmune reactions.

More... »


Accelrys purchases cloud-based HEOS tech from Scynexis

Tuesday, May 22, 2012 11:07 AM

Accelrys, a scientific enterprise R&D software and services company based in San Diego, has purchased the web-based Hit Explorer Operating System (HEOS) from Scynexis, a drug discovery and development company.

More... »

Datatrak selected as 2012 Crain's Leading EDGE honoree

Monday, May 21, 2012 12:08 PM

Datatrak International, a technology and services company focused on global eClinical solutions for the clinical trials industry, has been selected as a 2012 Crain's Leading EDGE award winner for the third consecutive year.

More... »

UMass Dartmouth MAB to house biomanufacturing startups

Friday, May 18, 2012 02:26 PM

The University of Massachusetts Dartmouth has broken ground on the site for their new Massachusetts Accelerator for Biomanufacturing (MAB), a facility for startup companies to test biomanufacturing methods and bioproducts located in Fall River, Mass.

More... »

Pharmos' levotofisopam trial in gout earns positive results

Friday, May 18, 2012 12:52 PM

Pharmos, a biopharmaceutical company based in Iselin, N.J., has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

More... »

KPCB closes $525 million fund

Friday, May 18, 2012 12:30 PM

Kleiner Perkins Caufield & Byers (KPCB) has successfully closed the KPCB 15, a $525 million venture capital fund focusing on investments in early-stage digital consumer and enterprise, green tech and life sciences companies.

More... »

City of Hope finds potential cure for type 1 diabetes

Friday, May 18, 2012 10:11 AM

City of Hope, a research, treatment and education center for cancer, diabetes and other life-threatening diseases based in Duarte, Calif., has developed a combination therapy to treat late-stage type 1 diabetes (T1D) that appears to offer a potential lifetime cure for the disease without toxic side effects. The laboratory study was published in the May 9, 2012, edition of Science Translational Medicine.

More... »

Synthetic Biologics appoints Carol Reed as senior vice president

Thursday, May 17, 2012 11:12 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic DNA-based therapeutics and disease-modifying medicines for serious illnesses, has appointed Carol Reed, M.D., as senior vice president of clinical & regulatory affairs.

More... »

Insmed appoints Hayden, Jr. as executive chairman

Thursday, May 17, 2012 10:45 AM

Insmed, a Monmouth Junction, N.J.-based biopharmaceutical company focused on inhalants, has appointed Donald J. Hayden, Jr. as executive chairman of the company's board of directors.

More... »

`

CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs